Drug Profile


Alternative Names: FZ-016; SKL-PSY/FZ-016

Latest Information Update: 01 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SK biopharmaceuticals
  • Developer Shanghai Medicilon; SK biopharmaceuticals
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bipolar disorders
  • Preclinical Anxiety disorders; Depressive disorders

Most Recent Events

  • 01 Dec 2015 Phase-I clinical trials in Bipolar disorders in USA (unspecified route)
  • 27 Mar 2013 SK biopharmaceuticals, Shanghai Medicilon and PKU International HealthCare Group agree to co-develop SKL-PSY for Depressive disorders and Bipolar depression
  • 19 Oct 2011 Preclinical trials in Bipolar disorders in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top